Skip to Main Content

Paper Details

A phase-1 trial of linsitinib (OSI-906) in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
Leuk Lymphoma
6
2021
IGF-1R, Linsitinib, OSI-906, anemia, anti, bone pain, bortezomib, cancer, dexamethasone, diarrhea, insulin-like growth factor-1 receptor, linsitinib, lung infection, multiple myeloma, neutropenia, patients, rash, relapsed/refractory, thrombocytopenia
Author NameAffiliation
Zhihua LiPrincess Margaret Cancer Centre
Suzanne TrudelPrincess Margaret Cancer Centre Ontario Cancer Institute
Suzanne TrudelPrincess Margaret Cancer Centre Ontario Cancer Institute
  • 1 - 3

Datasets

Release 1.2